Targeting a diverse spectrum of cancers.

Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.

Platform

Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.

Investors

DCPH

$20.79

0.64
10/23/17 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.

Latest News

Oct
03
2017
Deciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares Read More »
Sep
27
2017
Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering Read More »
Sep
11
2017
Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress Read More »